Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.
Grand Pharmaceutical Dividend Announcement
• Grand Pharmaceutical announced a annually dividend of HK$0.26 per ordinary share which will be made payable on 2024-06-27. Ex dividend date: 2024-06-06
• Grand Pharmaceutical annual dividend for 2024 was HK$0.26
• Grand Pharmaceutical annual dividend for 2023 was HK$0.14
• Grand Pharmaceutical's trailing twelve-month (TTM) dividend yield is 6.03%
• Grand Pharmaceutical's payout ratio for the trailing twelve months (TTM) is 38.32%
Grand Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-06-06 | HK$0.26 | annually | 2024-06-27 |
2023-06-09 | HK$0.14 | annually | 2023-06-27 |
2022-06-06 | HK$0.11 | annually | 2022-06-21 |
2021-06-08 | HK$0.11 | annually | 2021-06-23 |
2020-06-26 | HK$0.10 | annually | 2020-07-17 |
2019-06-12 | HK$0.09 | annually | 2019-06-28 |
Grand Pharmaceutical Dividend per year
Grand Pharmaceutical Dividend growth
Grand Pharmaceutical Dividend Yield
Grand Pharmaceutical current trailing twelve-month (TTM) dividend yield is 6.03%. Interested in purchasing Grand Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Grand Pharmaceutical Financial Ratios
Grand Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Grand Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Grand Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Grand Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Grand Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Grand Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Grand Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Grand Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Grand Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Grand Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Grand Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Grand Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.